Literature DB >> 31334773

Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis.

Jasvinder A Singh1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31334773     DOI： 10.1001/jama.2019.9056

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

Review 1.  The JAK/STAT signaling pathway: from bench to clinic.

Authors:  Xiaoyi Hu; Jing Li; Maorong Fu; Xia Zhao; Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2021-11-26

2.  Identification of the key differentially expressed genes and pathways involved in neutrophilia.

Authors:  Chengcheng He; Yingchun Zhang; Hongwei Luo; Bo Luo; Yancheng He; Nan Jiang; Yu Liang; Jingyuan Zeng; Yujiao Luo; Yujun Xian; Jiajia Liu; Xiaoli Zheng
Journal:  Innate Immun       Date:  2019-11-15       Impact factor: 2.680

3.  Computer aided designing of novel pyrrolopyridine derivatives as JAK1 inhibitors.

Authors:  Seketoulie Keretsu; Suparna Ghosh; Seung Joo Cho
Journal:  Sci Rep       Date:  2021-11-29       Impact factor: 4.379

4.  Umbelliferone and scopoletin target tyrosine kinases on fibroblast-like synoviocytes to block NF-κB signaling to combat rheumatoid arthritis.

Authors:  Qilei Chen; Wenmin Zhou; Yueming Huang; Yuanyang Tian; Sum Yi Wong; Wing Ki Lam; Ka Yee Ying; Jianye Zhang; Hubiao Chen
Journal:  Front Pharmacol       Date:  2022-07-25       Impact factor: 5.988
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.